THALIDOMIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H10N2O4
Molecular Weight	258.23
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1N(C2CCC(=O)NC2=O)C(=O)C3=CC=CC=C13

InChI

InChIKey=UEJJHQNACJXSKW-UHFFFAOYSA-N

InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)

HIDE SMILES / InChI

Molecular Formula	C13H10N2O4
Molecular Weight	258.23
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB01041
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf

Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right-handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans. In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor. Thalidomide is used for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Thalidomide is sold under the brand name Immunoprin, among others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Protein cereblon 10 Target ID: Q96SW2 Gene ID: 51185.0 Gene Symbol: CRBN Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB01041	Inhibitor 8504
TNF-alpha 17 Target ID: CHEMBL1825 Sources: http://www.drugbank.ca/drugs/DB01041	Inhibitor 8504	200.0 µM [IC50]
Nuclear factor NF-kappa-B p105 subunit 4 Target ID: CHEMBL3251 Sources: http://www.drugbank.ca/drugs/DB01041	Inhibitor 8504
Fibroblast growth factor receptor 2 25 Target ID: CHEMBL4142 Sources: http://www.drugbank.ca/drugs/DB01041	Inhibitor 8504
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11909713	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Multiple myeloma 159 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf	Primary		Approved 8583	THALOMID Approved Use THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Launch Date 1998
Erythema nodosum leprosum 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf	Primary		Approved 8583	THALOMID Approved Use THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Launch Date 1998

C_max

Value	Dose	Co-administered	Analyte	Population
2.82 μg/mL DRUG LABEL https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01041.pdf?1265922802	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2 mg/L REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15080764	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
36.4 μg × h/mL DRUG LABEL https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01041.pdf?1265922802	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
19.8 mg × h/L REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15080764	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
7.29 h DRUG LABEL https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01041.pdf?1265922802	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
6.17 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15080764	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
45% DRUG LABEL https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01041.pdf?1265922802	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
40% REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15080764	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg/m2 1 times / day multiple, oral MTD Dose: 400 mg/m2, 1 times / day Route: oral Route: multiple Dose: 400 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15514381	unhealthy, 11 Health Status: unhealthy Age Group: 11 Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/15514381	DLT: Somnolence... Dose limiting toxicities: Somnolence (20%) Sources: https://pubmed.ncbi.nlm.nih.gov/15514381
400 mg/m2 1 times / day multiple, oral MTD Dose: 400 mg/m2, 1 times / day Route: oral Route: multiple Dose: 400 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15514381	unhealthy, 11 Health Status: unhealthy Age Group: 11 Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/15514381	DLT: Ataxia... Dose limiting toxicities: Ataxia (16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/15514381
200 mg 2 times / day multiple, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16520988	unhealthy, 57 Health Status: unhealthy Age Group: 57 Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16520988	DLT: Dyspnea... Dose limiting toxicities: Dyspnea (50%) Sources: https://pubmed.ncbi.nlm.nih.gov/16520988
150 mg 2 times / day multiple, oral MTD Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16520988	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16520988	Sources: https://pubmed.ncbi.nlm.nih.gov/16520988
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf	Disc. AE: Fetal damage, Deep vein thrombosis... AEs leading to discontinuation/dose reduction: Fetal damage Deep vein thrombosis Pulmonary embolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf

AEs

AE	Significance	Dose	Population
Somnolence	20% DLT	400 mg/m2 1 times / day multiple, oral MTD Dose: 400 mg/m2, 1 times / day Route: oral Route: multiple Dose: 400 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15514381	unhealthy, 11 Health Status: unhealthy Age Group: 11 Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/15514381
Ataxia	16.7% DLT	400 mg/m2 1 times / day multiple, oral MTD Dose: 400 mg/m2, 1 times / day Route: oral Route: multiple Dose: 400 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15514381	unhealthy, 11 Health Status: unhealthy Age Group: 11 Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/15514381
Dyspnea	50% DLT	200 mg 2 times / day multiple, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16520988	unhealthy, 57 Health Status: unhealthy Age Group: 57 Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16520988
Deep vein thrombosis	Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf
Fetal damage	Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf
Pulmonary embolism	Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY545063	https://www.001chemical.com/chem/2614-06-4
001 Chemical	DY573864	https://www.001chemical.com/chem/841-67-8
001 Chemical	NO12019	https://www.001chemical.com/chem/50-35-1
3B Scientific (Wuhan) Corp	3B1-00279	http://www.3bsc.com/index/pro_info.php?id=20491
3B Scientific (Wuhan) Corp	3B3-004810	http://www.3bsc.com/index/pro_info.php?id=26694
AA Blocks	AA006UKW	https://www.aablocks.com/goods/Goods/detail?id=AA006UKW
Aaron Chemicals	AR006VCO	http://www.aaronchem.com/50-35-1
abcr GmbH	AB347541	http://www.abcr.com/shop/en/AB347541
AbMole Bioscience	M2225	http://www.abmole.com/products/thalidomide.html
Accela ChemBio Inc	SY052614	http://www.accelachem.com/cn/search.html?keyword=SY052614&attname=GoodsCode
Achemo Scientific Limited	AC-15639	http://www.achemo.com/search/?Keyword= 50-35-1
Achemtek	0104-022155	http://www.achemtek.com/50-35-1
AEchem Scientific Corp., USA	AE1-013135	http://www.aechemsc.com/info_products/AE1-013135.php
AHH Chemical co.,ltd	MT-59367	http://www.ahhchemical.com/product/MT-59367.html
AK Scientific, Inc. (AKSCI)	570010	http://www.aksci.com/item_detail.php?cat=570010
AK Scientific, Inc. (AKSCI)	J90042	http://www.aksci.com/item_detail.php?cat=J90042
Alfa Chemistry	AP50351-A	https://reagents.alfa-chemistry.com/product/thalidomide-cas-50-35-1-12112.html
Alfa Chemistry	AP50351-B	https://reagents.alfa-chemistry.com/product/thalidomide-cas-50-35-1-12113.html
Allbio Pharm Co., Ltd	AD04559	http://www.allbiopharm.com/product/n/AD04559
Alsachim	945	http://www.alsachim.com/product-C3127-glo.bal-view.html
Anward	ANW-53225	http://www.anward.com/pro_result/39676
Ark Pharm	AK-91024	http://www.arkpharminc.com/products/50-35-1.html
Aronis	ARONIS24496	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=1636
AstaTech, Inc.	35914	http://www.astatechinc.com/CPSResult.php?CRNO=36278
Aurum Pharmatech LLC	M-1523	http://www.Aurumpharmatech.com/Product/ProductDetails/M_1523
AvaChem Scientific	1620	http://www.avachem.com/productSearch.asp?1620
Axon MedChem	3324	https://www.axonmedchem.com/product/3324
BioChemPartner	BCP19772	http://www.biochempartner.com/50-35-1-BCP19772
BioCrick	BCC2248	http://www.biocrick.com/Thalidomide-BCC2248.html
BioSynth	W-105969	https://www.biosynth.com/en/products/chemical-intermediates/basic-intermediates/products/W-105969.html
BLD Pharm	BD153744	http://www.bldpharm.com/products/50-35-1.html
BOC Sciences	1219177-18-0	https://www.bocsci.com/thalidomide-d4-cas-1219177-18-0-item-255467.html
Boerchem	BC204656	http://www.boerchem.com/?product_34445.html
BroadPharm	BP-30256	https://www.broadpharm.com/web/product.php?catalog=BP-30256
Calbiochem	585970	http://www.emdbiosciences.com/product/585970
Chem Scene	CS-1084	http://www.chemscene.com/50-35-1.html
Chemenu	CM110594	http://www.chemenu.com/products/CM110594
ChemMol	30102213	http://www.chemmol.com/chemmol/30102213.html
ChemMol	44001905	http://www.chemmol.com/chemmol/44001905.html
ChemMol	49409208	http://www.chemmol.com/chemmol/49409208.html
ChemMol	97900477	http://www.chemmol.com/chemmol/97900477.html
Chemspace	CSSB00000747566	https://chem-space.com/CSSB00000747566
Clearsynth	CS-O-02490	https://www.clearsynth.com/en/CSO02490.html
Clearsynth	CS-T-61979	https://www.clearsynth.com/en/CST61979.html
Clearsynth	CS-T-61981	https://www.clearsynth.com/en/CST61981.html
CSNpharm	CSN12073	https://www.csnpharm.com/products/thalidomide.html
DC Chemicals	DC9009	http://www.dcchemicals.com/product_show-Thalidomide.html
Debye Scientific	DB-051759	http://www.debyesci.com/cas_50-35-1.html
EMD Millipore	585970	http://www.emdbiosciences.com/product/585970
eNovation Chemicals	D402693	https://www.enovationchem.com/ProductDetails.asp?ProductID=D402693
eNovation Chemicals	D480514	http://www.enovationchem.com/productDetails.asp?productID=D480514
Finetech	FT-0600001	http://www.finetechnology-ind.com/prod/detail/pub/2614-06-4.html
Finetech	FT-0602275	http://www.finetechnology-ind.com/prod/detail/pub/841-67-8.html
Finetech	FT-0631211	http://www.finetechnology-ind.com/prod/detail/pub/50-35-1.html
Finetech	FT-0675130	http://www.finetechnology-ind.com/prod/detail/pub/1219177-18-0.html
Glentham Life Sciences	GP4232	http://www.glentham.com/products/product/GP4232/
Hairui	HR134772	http://www.hairuichem.com/en/product/50-35-1.html
iChemical	EBD17683	http://www.ichemical.com/products/50-35-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00243537	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00243537
LGC Standards	LGCFOR0940.00	https://www.lgcstandards.com/US/en/p/LGCFOR0940.00
LGC Standards	MM0940.00	https://www.lgcstandards.com/US/en/p/MM0940.00
Lumtec	K0775	http://www.lumtec.com.tw/portal_c1_cnt_page.php?owner_num=c1_290785&button_num=c1&folder_id=32213&cnt_id=259223&search_field=&search_word=&search_field2=&search_word2=&search_field3=&search_word3=&bool1=&bool2=&search_type=1&up_page=2
mcule	MCULE-6327754946	https://mcule.com/MCULE-6327754946/
MedChem Express	HY-14658	https://www.medchemexpress.com/thalidomide.html
Molcore	CS12019	https://www.molcore.com/product/50-35-1
Molcore	MC545063	https://www.molcore.com/product/2614-06-4
Molcore	MC573864	https://www.molcore.com/product/841-67-8
OChem	5340	http://www.ocheminc.com/index.php?act=psearch&pid=153T873
Renno Tech	RP29207	http://www.rennotech.com/product_show.asp?id=34816
Selleck Chemicals	S1193	http://www.selleckchem.com/products/Thalidomide.html
Sigma-Aldrich	1652500_USP	https://www.sigmaaldrich.com/catalog/product/usp/1652500?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	T144_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/t144?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S548287	http://www.smolecule.com/products/s548287
Smolecule	S904079	https://www.smolecule.com/products/s904079
TCI (Tokyo Chemical Industry)	T2524	http://www.tcichemicals.com/eshop/en/us/commodity/T2524/index.html
THE BioTek	bt-287694	https://www.thebiotek.com/product/inhibitors/bt-287694
Tocris	652	https://www.tocris.com/products/thalidomide_0652
VladaChem	VL273087-500mg	https://www.vladachem.com/product.php?products=50-35-1
W&J PharmaChem	101000	http://www.wjpharmachem.com/new/101000.html
Yuhao Chemical	RT18984	http://www.chemyuhao.com/50-35-1.html

PubMed

Title	Date	PubMed
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.	2001-07-15	11435324
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.	2001-07-01	11418482
Clinical aspects and management of AIDS-related Kaposi's sarcoma.	2001-07	11423260
[Comparative treatment between thalidomide and transfer factor in severe atopic dermatitis].	2001-06-26	11421176
Neurobehavioral teratogenic effects of thalidomide in rats.	2001-06-22	11418267
Deep venous thrombosis and thalidomide therapy for multiple myeloma.	2001-06-21	11419443
Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis.	2001-06-16	11407104
Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro.	2001-06-16	11399936
[New concepts about atopic dermatitis].	2001-06-12	11398366
[Thalidomide and thrombosis: three observations].	2001-06-09	11433688
Thalidomide-induced amenorrhoea: two cases.	2001-06	11422077
[Thalidomide and cancer--revival of a drug].	2001-06	11420856
Alpha-glucosidase inhibitors with a 4,5,6,7-tetrachlorophthalimide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group.	2001-06	11411542
Disease controlling antirheumatic therapy in spondyloarthropathy.	2001-06	11409153
Thalidomide dose proportionality assessment following single doses to healthy subjects.	2001-06	11402635
Color Doppler ultrasonography of the superior mesenteric artery for prenatal ultrasonographic diagnosis of a left-sided congenital diaphragmatic hernia.	2001-06	11400943
Effectors of inflammation in actinic prurigo.	2001-06	11369907
Successful thalidomide treatment of severe infantile Behçet disease.	2001-05-19	11358558
[Sarcoidosis: thalidomide treatment in ten patients].	2001-05	11427794
Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess.	2001-05	11417421
Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases.	2001-05	11391677
Is infliximab effective for induction of remission in patients with ulcerative colitis?	2001-05	11383596
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.	2001-05	11380408
Transcending conventional therapies: the role of biologic and other novel therapies.	2001-05	11380043
Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.	2001-05	11380040
Synthesis and immunological activity of water-soluble thalidomide prodrugs.	2001-05	11377186
Thalidomide and its dermatologic uses.	2001-05	11370795
Intractable insomnia after cessation of treatment with thalidomide.	2001-05	11339241
Novel approaches to the treatment of chronic graft-versus-host disease.	2001-05	11322865
Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro.	2001-04	11354662
A cybernetic theory of morality and moral autonomy.	2001-04	11349358
Current management of cancer-associated anorexia and weight loss.	2001-04	11346935
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.	2001-04	11345648
Thalidomide use: past history and current implications for practice.	2001-04	11338756
The irreplaceable image. Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity.	2001-04	11325662
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.	2001-04	11325648
Thalidomide treatment of resistant or relapsed multiple myeloma patients.	2001-04	11325647
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.	2001-04	11325646
Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma.	2001-03-10	11416969
[Management of severe skin disorders in sarcoidosis].	2001-03	11357044
Thalidomide-induced sensory neuropathy.	2001-03	11345184
Targeting of vasculature in cancer and other angiogenic diseases.	2001-03	11334027
[Teratology, 40 years after the thalidomide tragedy].	2001-02	11387997
Pharmacotherapeutic options in inflammatory bowel disease: an update.	2001-02	11344586
Scleroderma.	2001-02	11328637
Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B.	2001-01	11367517
Thalidomide as an anti-angiogenic agent in relapsed gliomas.	2001-01	11349879
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.	2001	11400948
Thalidomide in gastrointestinal disorders.	2001	11398909
Managing cancer-related anorexia/cachexia.	2001	11324680

Patents

Sample Use Guides

In Vivo Use Guide

MM: 200 mg orally once daily. The recommended dose of dexamethasone is 40 mg/day on days 1-4, 9-12, and 17-20 every 28 days. • ENL: 100 to 300 mg/day for an episode of cutaneous ENL. Up to 400 mg/day for severe cutaneous ENL.

Route of Administration: Oral

In Vitro Use Guide

The minimum dose of thalidomide used (1 uM) inhibited TNF-α production in HTLV-1-infected subjects in vitro.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:21:32 GMT 2025` Edited by `admin` on `Mon Mar 31 18:21:32 GMT 2025`
Record UNII	4Z8R6ORS6L
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

THALIDOMIDE

Official Name

English

CELGENE

Preferred Name

English

K-17

Code

English

KEVADON

Brand Name

English

THALIDOMIDE [JAN]

Common Name

English

THALIDOMIDE [HSDB]

Common Name

English

Thalidomide [WHO-DD]

Common Name

English

THALIDOMIDE [MART.]

Common Name

English

2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE

Systematic Name

English

CONTERGAN

Brand Name

English

THALIDOMIDE [VANDF]

Common Name

English

DISTAVAL

Brand Name

English

(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE

Systematic Name

English

PHARMION

Brand Name

English

THALIDOMIDE [USAN]

Common Name

English

N-PHTHALYLGLUTAMIC ACID IMIDE

Common Name

English

.ALPHA.-PHTHALIMIDOGLUTARIMIDE

Common Name

English

NSC-527179

Code

English

MYRIN

Brand Name

English

NSC-66847

Code

English

N-(2,6-Dioxo-3-piperidyl)phthalimide

Systematic Name

English

thalidomide [INN]

Common Name

English

THALIDOMIDE [USP MONOGRAPH]

Common Name

English

THALIDOMIDE [USP-RS]

Common Name

English

NEUROSEDYN

Brand Name

English

THALIDOMIDE [ORANGE BOOK]

Common Name

English

1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-, (±)-

Systematic Name

English

THALOMID

Brand Name

English

2-(2,6-DIOXO-3-PIPERIDINYL)-1H-ISOINDOLE-1,3(2H)-DIONE

Systematic Name

English

SOFTENON

Brand Name

English

.ALPHA.-(N-PHTHALIMIDO)GLUTARIMIDE

Common Name

English

PANTOSEDIV

Brand Name

English

THALIDOMIDE [EMA EPAR]

Common Name

English

3-PHTHALIMIDOGLUTARIMIDE

Systematic Name

English

THALED

Brand Name

English

THALIDOMIDE [MI]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

43890